Seaport Therapeutics welcomes Denice Torres to its Board of Directors

– USA, MA –  Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the appointment of Denice Torres, J.D., to its Board of Directors.

Concurrently, Co-founder Dr. Michael Chen (Ph.D.) was named CSO and Eric Green was appointed COO.

About Denice Torres

Denice Torres brings notable public and private board experience to Seaport, including a position on the Board of Directors at Karuna Therapeutics until its acquisition by Bristol Myers Squibb in March 2024. She has over 30 years of P&L, strategy, and leadership experience in pharmaceuticals, consumer healthcare, and medical devices. Ms. Torres held several leadership positions at Johnson & Johnson, including President of J&J Consumer Healthcare, President of Janssen Neuroscience, and CSO for the medical device division. Before joining Johnson & Johnson, she held senior leadership roles at Eli Lilly, including Executive Director of Global Neuroscience and Head of Women’s Healthcare. Ms. Torres has received numerous awards, including the Healthcare Businesswomen’s Association Woman of the Year, Johnson & Johnson Working Mother of the Year, and the Johnson & Johnson Special Recognition Leadership Award for her work in diversity and inclusion.

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism, and reduce hepatotoxicity and other side effects. Seaport is led by an experienced team that was involved in inventing and advancing KarXT and other neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians, and key opinion leaders across neurological specialties.

For more information

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.